Regeneron Pharmaceuticals, Inc. (REGN)
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising competition.
Regeneron: Catching Another Wind
Regeneron has rebounded from regulatory and clinical setbacks, with Dupixent, Lynozyfic, and cemdisiran driving renewed growth momentum. REGN's pipeline is robust, targeting obesity, complement-mediated diseases, myeloma, solid tumors, and anticoagulation as strategic pillars for medium-term expansion. Valuation is revised to $1,230/sh, offering significant upside from current ~$750/sh levels, supported by a 15% FCF growth outlook and strong pipeline execution.
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
Regeneron will make its newly approved gene therapy Otarmeni for a rare, genetic form of hearing loss available for free in the U.S. The company hasn't decided how it will price the therapy overseas, Regeneron CEO Leonard Schleifer told CNBC on Friday.
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Regeneron (REGN) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S. patients following regulatory approval of the product.
FDA Approves First-Ever Gene Therapy to Restore Hearing
Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases Transcript
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
It will be a turbulent ride, but patient investors might come out of it much richer.
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
REGN or ILMN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
